

**PATENT**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

First Applicant:	EFENDIC Suad	Group Art Unit: 1646
Serial No.:	10/811646	Examiner: CHANDRA, GYAN
Application Date:	March 29, 2004	Conf No.: 3074
For:	USE OF GLP-1 OR ANALOGS IN TREATMENT OF MYOCARDIAL INFARCTION	
Docket No.:	X10822B	

**TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**Identification of Person Making This Disclaimer**

I, Mark J. Stewart, am employed by Eli Lilly and Company, and I am an attorney of record in the above-identified patent application. In that capacity, I am authorized to sign this disclaimer on behalf of Eli Lilly and Company.

**Identity of Assignee**

I hereby verify that the assignee owning all of the interest in this application is:

Eli Lilly and Company  
Lilly Corporate Center  
Indianapolis, Indiana 46285

**Recordal of Assignment in PTO**

The assignment was recorded on Dec. 1, 1997, Reel 8846, Frame 0135.

**Extent of Interest**

The extent of Eli Lilly and Company's interest is in the whole of this invention.

**Disclaimer**

I hereby disclaim the terminal part of any patent granted on this application, which would extend beyond the expiration date of United States Patent No. 6,747,006 and hereby agree that any patent granted on this application shall be enforceable only for and during such period that the legal title to the patent shall be the same as the legal title to United States Patent No. 6,747,006 .

I do not disclaim any terminal part of any patent granted on this application prior to the expiration date of the full statutory term of United States Patent No. 6,747,006 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its full statutory term other than as presently shortened by any terminal disclaimer.

**Fee Payment**

Please charge \$110.00, the fee set forth in 37 C.F.R. 1.20(d), and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840 in the name of Eli Lilly and Company.

ELI LILLY AND COMPANY

By: /Mark J. Stewart/

Mark J. Stewart  
Attorney for Applicants  
Registration No. 43,936  
Phone: 317-276-0280

Eli Lilly and Company  
Patent Division  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288  
November 2, 2006